A round of biotech and pharma finance leadership appointments landed across companies with active clinical programs and commercialization plans. CatalYm named Peter Garcia as CFO, bringing IPO and fundraising experience spanning oncology finance and debt/equity capital raising. eGenesis appointed Glenn S. Vraniak as CFO to support clinical studies across engineered organ transplantation programs including EGEN-2784 for kidney failure and acute-on-chronic liver failure. Hansa Biopharma selected Adam Cutler effective June 22. The CFO moves underscore ongoing balance-sheet and funding readiness as companies manage capital-intensive development programs and prepare for potential late-stage milestones.